The estimated Net Worth of Capital Ltd Portfolio Servi... is at least $122 Million dollars as of 7 August 2020. Capital Servi owns over 24,484,904 units of Marker Therapeutics stock worth over $23,990,547 and over the last 12 years Capital sold MRKR stock worth over $98,290,581.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Capital Servi MRKR stock SEC Form 4 insiders trading
Capital has made over 10 trades of the Marker Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Capital sold 24,484,904 units of MRKR stock worth $80,065,636 on 7 August 2020.
The largest trade Capital's ever made was selling 24,484,904 units of Marker Therapeutics stock on 7 August 2020 worth over $80,065,636. On average, Capital trades about 2,428,230 units every 124 days since 2013. As of 7 August 2020 Capital still owns at least 8,629,693 units of Marker Therapeutics stock.
You can see the complete history of Capital Servi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Marker Therapeutics
Over the last 6 years, insiders at Marker Therapeutics have traded over $0 worth of Marker Therapeutics stock and bought 60,748,562 units worth $106,570,272 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Marker Therapeutics executives and independent directors trade stock every 38 days with the average trade being worth of $9,934,177. The most recent stock trade was executed by Frederick Gerald Wasserman on 18 May 2021, trading 10,000 units of MRKR stock currently worth $24,100.
What does Marker Therapeutics do?
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
What does Marker Therapeutics's logo look like?
Complete history of Capital Servi stock trades at Cyclacel Pharmaceuticals Inc, Cytokinetics Inc, iBio Inc, and Marker Therapeutics
Marker Therapeutics executives and stock owners
Marker Therapeutics executives and other stock owners filed with the SEC include:
-
Peter L. Hoang MBA,
Pres, CEO & Director -
Anthony H. Kim,
Chief Financial Officer -
Dr. Mythili Koneru M.D., Ph.D.,
Chief Medical Officer -
Dr. Robert Z. Florkiewicz Sr.,
Sr. Director of Molecular Biology & Virology -
Dr. Nadia Agopyan Ph.D.,
Sr. VP of Regulatory Affairs -
Edmund Cheung,
VP of HR -
Elizabeth Donnelly,
Director of Admin. -
Michael J. Loiacono,
Chief Accounting Officer, Treasurer & Sec. -
Dr. Juan F. Vera M.D.,
Co-Founder, COO, Chief Scientific Officer & Director -
Gerald Garrett,
Vice President, Clinical Ops. -
Enterprise Associates 16, L...,
-
Ali Behbahani,
10% owner -
Forest Baskett,
10% owner -
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Joshua Makower,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Paul Edward Walker,
10% owner -
Mythili Koneru,
Chief Medical Officer -
Capital Ltd Portfolio Servi...,
-
Steve Elms,
Director -
Anthony H. Kim,
Chief Financial Officer -
Tsvetelina P Hoang,
VP, Research and Development -
Frederick Gerald Wasserman,
Director -
David Laskow Pooley,
Director -
Nadia Agopyan,
SVP, Regulatory Affairs -
John Robert Wilson,
Director -
Anna Szymanska,
Vice President, Quality -
Norman David Eansor,
Director -
Juan Vera,
President and CEO -
Peter L. Hoang,
President and CEO -
Michael Loiacono,
Chief Accounting Officer -
Ann M. Leen,
Chief Scientific Officer -
Katharine Knobil,
Director